Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Cash (2023 - 2025)

CG Oncology's Change in Cash history spans 3 years, with the latest figure at -$12.7 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 105.92% year-over-year to -$12.7 million; the TTM value through Dec 2025 reached -$224.6 million, down 190.26%, while the annual FY2025 figure was -$224.6 million, 190.26% down from the prior year.
  • Change in Cash reached -$12.7 million in Q4 2025 per CGON's latest filing, down from $30.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $213.7 million in Q4 2024 to a low of -$215.6 million in Q1 2025.
  • Average Change in Cash over 3 years is -$4.6 million, with a median of -$7.3 million recorded in 2023.
  • Peak YoY movement for Change in Cash: skyrocketed 10745.59% in 2024, then plummeted 411.55% in 2025.
  • A 3-year view of Change in Cash shows it stood at -$2.0 million in 2023, then surged by 10745.59% to $213.7 million in 2024, then plummeted by 105.92% to -$12.7 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Change in Cash are -$12.7 million (Q4 2025), $30.5 million (Q3 2025), and -$26.8 million (Q2 2025).